Sirignano Pasqualino, Mangialardi Nicola, Nespola Martina, Aloisi Francesco, Orrico Matteo, Ronchey Sonia, Del Porto Flavia, Taurino Maurizio
Vascular and Endovascular Surgery Unit, Sant'Andrea Hospital, Department of Surgery Paride Stefanini, Sapienza University of Rome, 00189 Rome, Italy.
Department of Vascular Surgery, Ospedale San Camillo-Forlanini, 00152 Rome, Italy.
J Pers Med. 2022 Feb 24;12(3):339. doi: 10.3390/jpm12030339.
Introduction: The aim of the present study is to report the outcome of patients presenting an isolated type II endoleak (TIIEL) requiring reintervention and to identify clinical and anatomical characteristics potentially implicated in refractory TIIEL occurrence and fate. Materials and Methods: A multicenter retrospective study on TIIEL requiring reintervention was conducted between January 2003 and December 2020. Demographic and clinical characteristics, procedural technical aspects, reinterventions, and outcomes were recorded. TIIEL determining sac expansion greater than 10 mm underwent a further endovascular procedure aiming to exclude aneurismal sac. Redo endovascular procedures were performed via endoleak nidus direct embolization and/or aortic side branches occlusion. TIIELs responsible for persisting aneurysmal sac perfusion 6 months after redo endovascular procedures were classified as “refractory” and submitted to open conversion. Results: A total of 102 TIIEL requiring reintervention were included in the final analysis. Eighty-eight (86.27%) patients were male, the mean age was 77.32 ± 8.08 years, and in 72.55% of cases the American Society of Anaesthesiologists (ASA) class was ≥3. The mean aortic diameter was 64.7 ± 14.02 mm, half of treated patients had a patent inferior mesenteric artery (IMA), and 44.11% ≥ 3 couples of patent lumbar arteries (LA). In 49 cases (48.03%) standard endovascular aneurysm repair (EVAR) procedure was completed without adjunctive maneuvers. All enrolled patients were initially submitted to a further endovascular procedure once TIIEL requiring reintervention was diagnosed; 57 patients underwent LAs or IMA embolization (55.87%), 42 transarterial aneurismal sac embolization (41.17%), and three (2.96%) laparoscopic ostial ligations of the inferior mesenteric artery. During a mean follow-up of 15.22 ± 7.57 months (7−48), a redo endovascular approach was able to ensure complete sac exclusion in 52 cases, while 50 patients presented a still evident refractory TIIEL and therefore a surgical conversion or semiconversion was conducted. At the univariate analysis refractory TIIEL patients were significantly different from those who did not develop the complication in terms of preoperative clinical, morphological characteristics, and initial EVAR procedures: coronary artery disease occurrence (p = 0.005, OR: 3.18, CI95%: 1.3−7.2); preoperative abdominal aortic aneurysm (AAA) sac diameter (p = 0.0055); IMA patency (p = 0.016, OR: 2.64, CI95%: 1.18−5.90); three or more patent LAs; isolated standard EVAR without adjunctive procedures (p > 0.0001; OR: 9.48, CI95%: 3.84−23.4). Conclusions: Our experience seems to demonstrate that it is reasonable to try to preoperatively identify those patients who will develop a refractory TIIEL after EVAR and those with a TIIEL requiring reintervention for whom a simple endovascular redo will not be enough, needing surgical conversion.
本研究的目的是报告需要再次干预的孤立性Ⅱ型内漏(TIIEL)患者的治疗结果,并确定可能与难治性TIIEL的发生和转归相关的临床和解剖学特征。材料与方法:对2003年1月至2020年12月期间需要再次干预的TIIEL进行了一项多中心回顾性研究。记录了人口统计学和临床特征、手术技术方面、再次干预情况及结果。对于TIIEL导致瘤腔扩张大于10mm的患者,进行了进一步的血管内手术,旨在排除动脉瘤瘤腔。再次血管内手术通过内漏病灶直接栓塞和/或主动脉侧支闭塞进行。在再次血管内手术后6个月仍导致动脉瘤瘤腔持续灌注的TIIEL被归类为“难治性”,并进行开放手术转换。结果:最终分析纳入了102例需要再次干预的TIIEL患者。88例(86.27%)为男性,平均年龄为77.32±8.08岁,72.55%的病例美国麻醉医师协会(ASA)分级≥3级。平均主动脉直径为64.7±14.02mm,半数接受治疗的患者肠系膜下动脉(IMA)通畅,44.11%有≥3对通畅的腰动脉(LA)。49例(48.03%)患者完成了标准的血管内动脉瘤修复(EVAR)手术,未进行辅助操作。一旦诊断出需要再次干预的TIIEL,所有纳入患者均首先接受了进一步的血管内手术;57例患者进行了腰动脉或肠系膜下动脉栓塞(55.87%),42例进行了经动脉动脉瘤瘤腔栓塞(41.17%),3例(2.96%)进行了肠系膜下动脉的腹腔镜开口结扎术。在平均15.22±7.57个月(7 - 48个月)的随访期间,再次血管内手术能够确保52例患者的瘤腔完全排除,而50例患者仍存在明显的难治性TIIEL,因此进行了手术转换或半转换。在单因素分析中,难治性TIIEL患者在术前临床、形态学特征和初始EVAR手术方面与未发生该并发症的患者有显著差异:冠心病发生率(p = 0.005,OR:3.18,CI95%:1.3 - 7.2);术前腹主动脉瘤(AAA)瘤腔直径(p = 0.0055);肠系膜下动脉通畅情况(p = 0.016,OR:2.64,CI95%:1.18 - 5.90);3条或更多通畅的腰动脉;单纯标准EVAR手术未进行辅助操作(p > 0.0001;OR:9.48,CI95%:3.84 - 23.4)。结论:我们的经验似乎表明,术前试图识别那些在EVAR后将发生难治性TIIEL的患者以及那些需要再次干预且单纯血管内再次手术不足够而需要手术转换的TIIEL患者是合理的。